Purchase Order 75N95022P00131

The Department of Health and Human Services' National Institutes of Health National Institute on Drug Abuse awarded a firm fixed-price purchase order valued at $22,500 to the University of Kansas Center for Research, Inc. This award is pursuant to a request for quote to develop a manufacturable tablet formulation of the compound NCGC72 for use in dog sarcoma clinical studies. The prime contractor will non-GMP manufacture 1,500 tablets total, with 1,000 tablets at 50mg dosage and 500 tablets at...

The National Institute on Drug Abuse issued a $1,838,614.86 delivery order to Altasciences Clinical Kansas Inc. on September 25, 2023, for pharmacokinetic and pharmacodynamic trials supporting Phase 1 cocaine drug interaction studies in medication development for substance use disorders. The order runs through October 22, 2025. Place of performance is Shawnee Mission, Kansas. The delivery order is priced on a firm fixed-price basis and was issued under a $21 million single-award indefinite...

<p>The National Institute on Drug Abuse issued a purchase order to North David K for $14,400.00 on June 14, 2022, for Institutional Animal Care and Use Committee (IACUC) support services. Work is performed in Indian Head, Maryland. The order carries a firm fixed price and an ultimate completion date of June 13, 2025. This purchase order funded the FY26 UDO Initiative and used no set-aside category.</p>

<p>The National Institute on Drug Abuse awarded a purchase order to Life Technologies Corporation for $16,990.88 on July 30, 2019. The order carries no set-aside designation and has a firm fixed price structure. Performance takes place in Carlsbad, California. The ultimate completion date is July 31, 2022. The order is part of the FY26 UDO Initiative.</p>

The National Institute on Drug Abuse issued a purchase order to Darryle Schoepp for pharmacology consulting services on February 23, 2022, with a ceiling value of $69,078.40. The order is set aside as a Total Small Business acquisition. Work is performed in Ardmore, Pennsylvania, and covers pharmacology consulting in support of drug discovery and developmental programs and the associated Blueprint Neurotherapeutics Network external oversight committee for NINDS. Pricing is labor-hour based....

The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse awarded a $10,465 firm fixed price purchase order to Cambrex High Point, Inc. to support retesting of the GLWL-01 reference standard and project specific funding. Cambrex will perform the work in Baltimore, Maryland over a one year period from July 2023 through July 2024. The National Institute on Drug Abuse conducts important biomedical research on drug abuse and addiction to improve...

This is a firm-fixed-price delivery order contract awarded by the National Institute on Drug Abuse (NIDA), a civilian federal agency, to Altasciences Clinical Kansas Inc., a for-profit contract research organization (CRO) located in Overland Park, Kansas. The contract is for a study to evaluate the safety, tolerability, and pharmacokinetics of an investigational agent. The period of performance is from September 3, 2024, to March 11, 2026, with a ceiling value of $1,724,198.59. The contract...

The National Institute on Drug Abuse awarded a purchase order to Pharmaron, Inc. for $117,435 on August 9, 2022, to evaluate NNMT inhibitors in metabolic disorders. The order is firm fixed price with no small business set-aside. Place of performance is Louisville, Kentucky. The ultimate completion date was August 8, 2023. The award was issued as part of an HHS UDO SPRINT exercise to de-obligate unexpended and expiring fiscal year 2021 funding in accordance with 31 U.S.C. Section 1552(a) ahead of...

The National Institute on Drug Abuse issued a purchase order to Children's Hospital Medical Center valued at $28,175.00 on July 31, 2018, to administratively de-obligate unexpended and expiring fiscal year 2021 funding in accordance with 31 U.S.C. Section 1552(a) in preparation for the September 30, 2026 closing of the period of availability of these fiscal year funds. Performance occurs at Bethesda, Maryland. The order is firm fixed price with no set-aside designation. Ultimate completion...

The National Institute of Neurological Disorders and Stroke issued a delivery order to Mriglobal on August 15, 2026, with a ceiling value of $2,534,752, for drug manufacturing and formulation under the NINDS Drug Manufacturing and Formulation Program, specifically for a selective CB2 agonist. The order is issued under the NINDS $49.99 million multiple-award Drug Manufacturing and Formulation Program contract (awarded May 2026, through May 2036). Place of performance is Kansas City, MO. Period of...